CNS Pharmaceuticals reports Q2 EPS ($6.42) vs. ($4,049.20) last year

“Every decision we make is grounded in our science and driven by a sense of urgency and responsibility to the patients and families counting on us for better outcomes. We are making excellent progress in our development strategy for TPI 287, working rapidly toward commencing a Phase 2 study for the treatment of GBM in the first half of 2026. Looking ahead, we are continuing to leverage our operational experience and global infrastructure to support TPI 287 while working to get our trial up and running and begin dosing patients with this exciting drug candidate,” commented John Climaco, CEO of CNS Pharmaceuticals (CNSP).